Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1995-05-03
2002-09-03
Ulm, John (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C536S023500
Reexamination Certificate
active
06444789
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to human CD16-II protein variants, DNA sequences coding for them, their use in therapy and/or in diagnosis of autoimmune diseases and inflammatory illnesses, as well as pharmaceutical compositions comprising them.
BACKGROUND OF THE INVENTION
CD16, also called Fc&ggr; receptor-III (Fc&ggr;R-III), is a low affinity receptor for Immunoglobulin G (IgG). With other receptors of the immunoglobulin Fc portion (Fc&ggr;R-I, Fc&ggr;R-II, Fc&egr;R-I), CD16 plays an important role in mediating autoimmunity and inflammatory responses.
Studies using monoclonal. antibodies against CD16 have established this receptor's role in removing immune complexes from circulation and in mediating antibody-dependent cell mediated cellular cytotoxicity (ADCC) (see for example Van de Winkel et al.,
Immunol. Today,
14, 1993, pp.215-221). The binding of IgG with CD16 elicits NK/LGL cell activation and triggers ADCC. ADCC can be halted in the presence of high levels of soluble CD16.
It has been found (see Mathiot et al.,
J. Clin. Immunol.,
13, (1), 1993, pp. 41-8) that the level of soluble CD16 was significantly decreased in patients with multiple myeloma compared with healthy volunteers. In addition a stage-dependent decrease of soluble CD16 was observed, with a highly significant difference between stage I and stages II+III myeloma patients. Therefore the measurement of soluble CD16 in serum is both a diagnostic and a prognostic marker of myeloma, which can be useful to define and guide novel immunomodulatory therapies of the disease.
It has further been found that CD16 is present in human serum and other body fluids and is elevated at sites of inflammation (see Fleit et al.,
Blood,
79, (10), 1992, pp. 2721-8).
From Ravetch et al. (
J. Exp. Med.,
170, 1989, pp. 481-97) it is clear that there are at least two isoforms of human CD16, type 1 and type 2, that can be designated as CD16-I and CD16-II, respectively These two isoforms of CD16 are encoded by two separate but elated genes, NA1 and NA2.
From Scallon et al. (
PNAS USA,
86, pp.5079-83, July 1989) it is evident that CD16-I and CD16-II are distinct in both structure and cellular expression. CD16-I is expressed predominantly on the surface of neutrophils and monocytes, whereas CD16-II is expressed predominantly on the surface of macrophages, natural killer cells and large granular lymphocytes (NK/LGL). Furthermore, these two types of CD-16 are associated with the cell surface via two distinct mechanisms: CD16 type I is associated with the cell surface by glycosyl-phosphotidylinositol (GPI) linkage; whereas CD16 type II is anchored on the membrane with about 20 extra amino acids. Furthermore, the N-terminus of the mature CD16 has been investigated and the methionine residue at position 18 was identified as the N-terminal residue of the mature protein. Thus, the initial translation product contains a 17-amino acid signal peptide. The transmembrane region of CD16-II is shown to be from amino acid 209 to 229, whereas CD16-I is reported lacking transmembranal and cytoplasmic domains.
It has been determined that a single amino acid at position 203, Ser, found in isoform I versus Phe, found in type II, determines the membrane anchoring mechanism (see Lanier et al.,
Science,
246, 1989, pp. 1611-3).
For human CD16-I, a polymorphism has been reported previously, as is evident from
FIG. 1
, whereas only one alternative nucleic acid sequence encoding CD16-II has been published until now (Ravetch et al.,
J. Exp. Med.,
170, 1989, pp. 481-97).
Recently, Huizinga et al. (see
Blood,
76, pp. 1927-, 1990) published evidence that CD16-I deficiency is related to neonatal isoimmune neutropenia.
Bredius et al. (in
Immunology,
83, pp. 624-, 1994) reported specifically that CD16-I-NA1 exhibited a 21-25% higher IgG1 mediated phagocytosis than CD16-I-NA2.
It has been reported that circulating levels of soluble CD16 are reduced in Multiple Myeloma, and an inhibitory effect of sCD16 on myeloma cells and pokeweed mitogen (PWM)-induced B-cell proliferation have been reported (see, respectively, Hoover et al.,
J. Cli. Inve.,
95(1), pp.241-7, 1995) and Teillaud et al.,
Blood,
82(10), 15 November 1993).
European Patent Application EP 343 950 generally discloses soluble and membrane-bound human Fc&ggr;R-III polypeptides as well as nucleic acids capable of encoding the same. In particular, the .sequence of a CD16-I variant and the sequence of CD16-II are shown in the Figures. This patent application further discloses various utilities for these polypeptides.
Citation of any document herein is not intended as an admission that such document is pertinent prior art, or considered material to the patentability of any claim of the present application. Any statement as to content or a date of any document is based on the information available to applicant at the time of filing and does not constitute an admission as to the correctness of such a statement.
SUMMARY OF THE INVENTION
The present invention is based on the discovery of new human CD16-II variant clones. They have been isolated by using an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction)-based strategy using designed isoform-specific oligonucleotide primers. In particular, from a pooled human lung RNA extract, CD16-II has been amplified via RT-PCR. These CD16-II variants provide a therapeutic intervening approach and/or a diagnostic tool for autoimmune and inflammatory diseases. As they are natural variants of the CD16-II sequence previously published, the polypeptides of the present invention can be used for any of the utilities previously disclosed for CD16-II. All of the utilities for CD16-II made evident from any of the publications disclosed herein are hereby incorporated herein by reference, and particularly those in European application 343,950.
The main object of the present invention are the polypeptides comprising respectively the SEQ ID NO: 1, 2, 3 and 4.
Another object of the invention are the DNA molecules comprising the DNA sequences coding for each of the four polypeptides, as shown in
FIG. 3
, including nucleotide sequences substantially the same. “Nucleotide sequences substantially the same” includes all other nucleic acid sequences which, by virtue of the degeneracy of the genetic code, also code for the given amino acid sequences. Preparation of an alternative nucleotide sequence encoding the same polypeptide but differing from the natural sequence due to changes permitted by the known degeneracy of the genetic code, can be achieved by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the polypeptide of the present invention. Site-specific mutagenesis allows the production of variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 complementing nucleotides on each side of the sequence being altered. In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by publications such as Adelman et al.,
DNA,
2:183 (1983), the disclosure of which is incorporated herein by reference. As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, for example, as disclosed by Messing et al.,
Third Cleveland Symposium on Macromolecules and Recombinant DNA,
A. Walton, editor, Elsevier, Amsterdam (1981), the disclosure of which is incorporated herein by reference. These phage are readily available commercially and their use is generally well known to those skilled in the art. Alternatively, plasmid vectors that
Applied Research Systems ARS Holding N.V.
Browdy and Neimark , P.L.L.C.
Ulm John
LandOfFree
CD16-II variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD16-II variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD16-II variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2866225